Got Observations?: Ensuring Effective Responses to FDA 483s and Warning Letters

January 21, 2026 | 12:00PM–1:30PM ET | Live Webinar

Overview

Join our panel of experts for a practical deep dive into effectively responding to FDA 483s and Warning Letters. This webinar, tailored especially for the life sciences industry, features real-world case studies and actionable strategies to help you avoid escalation and safeguard your organization’s credibility following notification of FDA inspection observations. Learn how to develop thorough, well-reasoned responses to these notices, identify common pitfalls, and align your approach with FDA’s expectations.

$149

Members

$249

Non-Members

Speakers

Donald Ashley
Read Bio
Principal, Regulatory Compliance, ELIQUENT Life Sciences

David Crome
Read Bio
Managing Director, Quality & Compliance UK, Ireland & India, ProPharma Group

Joe McGinnis
Read Bio
Senior Director, Pharmaceutical Regulatory Compliance—Americas, Johnson & Johnson

Kalie Richardson
Read Bio
Director, Hyman, Phelps & McNamara, PC